Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × epratuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma 2 Recurrence 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 102 Dexamethasone 57 Cytarabine 47 Rituximab 46 fludarabine phosphate 45 fludarabine 44 Gemcitabine 35 Lenalidomide 34 Etoposide 33 Peripheral Blood Stem Cell Transplantation 32 pembrolizumab 30 Radiotherapy 30 Filgrastim 29 Busulfan 28 Cyclosporine 26 Cisplatin 26 Carboplatin 26 Methotrexate 25 Melphalan 25 venetoclax 23 Paclitaxel 23 Mycophenolic Acid 23 Bortezomib 23 Whole-Body Irradiation 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Antilymphocyte Serum 19 Temozolomide 18 Oxaliplatin 18 Decitabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡